Theralase Technologies Inc. (TSXV:TLT), a biopharma stock, shot up after announcing results from its Phase Ib Non-Muscle Invasive Bladder Cancer clinical study
A potential cancer treatment breakthrough produced healthy gains for a biopharma stock Thursday. Here’s some small stocks making big moves on Thursday, November 8, 2018 (as of 4 pm EST):
Theralase Technologies Inc. (TSXV:TLT), a biopharma stock, surged 21% to $0.35 on Thursday after announcing that patient five, who enrolled and was treated in the recently-completed Phase Ib Non-Muscle Invasive Bladder Cancer clinical study using light-activated Photo Dynamic Compounds and their associated drug formulations, demonstrated no tumour recurrence or presence of disease at the 90 day, 180 day, or 270 day clinical and cystoscopy assessment post treatment.
As well, shares of Freshii Inc. (TSX:FRII) sank 33% to $2.65 as the health and wellness food retailer said it has decided to withdraw its financial outlook through fiscal 2019.
Canada Jetlines Ltd. (TSXV:JET), meanwhile, reported that it intends to offer ultra-low fare service to the Montréal region from Aéroport Montréal Saint-Hubert Longueuil. Canada Jetlines stock moved up 19% to $0.68 following the announcement.
Finally, ProntoForms Corporation (TSXV:PFM) shares gained 9% to $0.37 after the provider of smart mobile forms for enterprise announced that its recurring revenue in Q3 2018 increased 24% to $2,780,814.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Theralase Technologies Inc. (TSXV:TLT), a biopharma stock, surged 21% to $0.35 on Thursday after announcing that patient five, who enrolled and was treated in the recently-completed Phase Ib Non-Muscle Invasive Bladder Cancer clinical study using light-activated Photo Dynamic Compounds and their associated drug formulations, demonstrated no tumour recurrence or presence of disease at the 90 day, 180 day, or 270 day clinical and cystoscopy assessment post treatment.
